neihulizumab
mAbexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00848055)
Timeline
Indications
Mechanism of action
- P-selectin glycoprotein ligand 1INHIBITOR
P-selectin glycoprotein ligand 1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297861 ↗
Also known as
- abgn168
- neihulizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04144036 | Phase 1 | Dec 15, 2019 | Medical College of Wisconsin |
| NCT03327857 | Phase 1 | May 31, 2018 | AltruBio, University of Washington |
| NCT03298022 | Phase 2 | Apr 10, 2018 | AltruBio, University of Chicago |
| NCT02694770 | Phase 2 | Jul 1, 2016 | AltruBio, University of Texas at Houston, University of Washington |
| NCT00848055 | Phase 1 | Dec 1, 2008 | Boehringer Ingelheim |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AltruBio | For profit | 3 | 3 | 2 | 2016 |
| University of Washington | Academic/Hospital | 2 | 0 | 2 | 2016 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2008 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2016 |
6 organizations
Page 1 / 1